Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (AGIO) and uniQure (QURE).
Agios Pharma (AGIO)
In a report released today, Chad Messer from Needham assigned a Buy rating to Agios Pharma, with a price target of $69.00. The company’s shares closed last Monday at $40.80.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 12.9% and a 49.3% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agios Pharma with a $66.86 average price target, which is a 51.6% upside from current levels. In a report issued on December 8, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.
See today’s analyst top recommended stocks >>
uniQure (QURE)
Mizuho Securities analyst Difei Yang maintained a Hold rating on uniQure today and set a price target of $52.00. The company’s shares closed last Monday at $38.51, close to its 52-week low of $34.38.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.0% and a 37.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Selecta Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure with a $68.56 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.